共检索3条数据Total:3
Department of Biological Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.; John B. Little Center for Radiation Sciences, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.; Department of Virology, Faculty of Medicine, Iran University of Medical Science, Tehran 1449614535, Iran.; Department of Biological Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.; Department of Virology, Faculty of Medicine, Iran University of Medical Science, Tehran 1449614535, Iran.; Department of Family Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.; Department of Biological Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.
The current study systematically reviewed, summarized and meta-analyzed the clinical features of the vaccines in clinical trials to provide a better estimate of their efficacy, side effects and immunogenicity. All relevant publications were systematically searched and collected from major databases up to 12 March 2021. A total of 25 RCTs (123 datasets), 58,889 cases that received the COVID-19 vaccine and 46,638 controls who received placebo were included in the meta-analysis. In total, mRNA-based and adenovirus-vectored COVID-19 vaccines had 94.6% (95% CI 0.936-0.954) and 80.2% (95% CI 0.56-0.93) efficacy in phase II/III RCTs, respectively. Efficacy of the adenovirus-vectored vaccine after the first (97.6%; 95% CI 0.939-0.997) and second (98.2%; 95% CI 0.980-0.984) doses was the highest against receptor-binding domain (RBD) antigen after 3 weeks of injections. The mRNA-based vaccines had the highest level of side effects reported except for diarrhea and arthralgia. Aluminum-adjuvanted
2021-05-30
Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada.; Department of Virology, Faculty of Medicine, Iran University of Medical Science, Tehran, Iran.; Department of Virology, Faculty of Medicine, Iran University of Medical Science, Tehran, Iran.; Department of Virology, Faculty of Medicine, Iran University of Medical Science, Tehran, Iran.; Department of Virology, Faculty of Medicine, Iran University of Medical Science, Tehran, Iran.; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Center for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Division of GI, Trauma and Endocrine Surgery, Department of Surgery, University of Colorado, Denver, Colorado, USA.; Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada.
We compared clinical symptoms, laboratory findings, radiographic signs and outcomes of COVID-19 and influenza to identify unique features. Depending on the heterogeneity test, we used either random or fixed-effect models to analyse the appropriateness of the pooled results. Overall, 540 articles included in this study; 75,164 cases of COVID-19 (157 studies), 113,818 influenza type A (251 studies) and 9266 influenza type B patients (47 studies) were included. Runny nose, dyspnoea, sore throat and rhinorrhoea were less frequent symptoms in COVID-19 cases (14%, 15%, 11.5% and 9.5%, respectively) in comparison to influenza type A (70%, 45.5%, 49% and 44.5%, respectively) and type B (74%, 33%, 38% and 49%, respectively). Most of the patients with COVID-19 had abnormal chest radiology (84%, p < 0.001) in comparison to influenza type A (57%, p < 0.001) and B (33%, p < 0.001). The incubation period in COVID-19 (6.4 days estimated) was longer than influenza type A (3.4 days). Likewise, the
2021-09-30
Department of Obstetrics, Gynecology, and Perinatology, Hamedan University of Medical Science, Hamedan, Iran.; Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada.; Neuroscience Research Center, Guilan University of Medical Sciences, Rasht, Iran.; Department of Virology, Faculty of Medicine, Iran University of Medical Science, Tehran, Iran.; Department of Pediatrics, Division of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Department of Obstetrics, Gynecology, and Perinatology, Hamedan University of Medical Science, Hamedan, Iran.; Department of Radiology, Hashemi Rafsanjani Hospital, North Khorasan University of Medical Sciences, Shirvan, Iran.; Department of Biological Science, University of Calgary, Calgary, Alberta, Canada.; John B. Little Center for Radiation Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.; Department of Virology, Faculty of Medicine, Iran University of Medical Science, Tehran, Iran.; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Center of Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
In a large-scale study, 128176 non-pregnant patients (228 studies) and 10000 pregnant patients (121 studies) confirmed COVID-19 cases included in this Meta-Analysis. The mean (confidence interval [CI]) of age and gestational age of admission (GA) in pregnant women was 33 (28-37) years old and 36 (34-37) weeks, respectively. Pregnant women show the same manifestations of COVID-19 as non-pregnant adult patients. Fever (pregnant: 75.5%; non-pregnant: 74%) and cough (pregnant: 48.5%; non-pregnant: 53.5%) are the most common symptoms in both groups followed by myalgia (26.5%) and chill (25%) in pregnant and dysgeusia (27%) and fatigue (26.5%) in non-pregnant patients. Pregnant women are less probable to show cough (odds ratio [OR] 0.7; 95% CI 0.67-0.75), fatigue (OR: 0.58; CI: 0.54-0.61), sore throat (OR: 0.66; CI: 0.61-0.7), headache (OR: 0.55; CI: 0.55-0.58) and diarrhea (OR: 0.46; CI: 0.4-0.51) than non-pregnant adult patients. The most common imaging found in pregnant women is